Pharmacokinetics of (-)-β-D-dioxolane guanine and prodrug (-)-β-D-2,6- diaminopurine dioxolane in rats and monkeys

AIDS Research and Human Retroviruses

Volumn 15, Issue 18, 1999, Pages 1625-1630

  Chen, Huachun ^a   Schinazi, Raymond F ^b,c,d   Rajagopalan, Prabhu ^a   Gao, Zhiling ^a   Chu, Chung K ^a   McClure, Harold M ^b   Boudinot, F Douglas ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b EMORY UNIVERSITY   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BETA DEXTRO 2,6 DIAMINOPURINE DIOXOLANE; BETA DEXTRO DIOXOLANE GUANINE; LAMIVUDINE; PRODRUG; STAVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG METABOLISM; HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; INTRAVENOUS DRUG ADMINISTRATION; MALE; MONKEY; NONHUMAN; PRIORITY JOURNAL; RAT; URINARY EXCRETION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; DIOXOLANES; GUANOSINE; INJECTIONS, INTRAVENOUS; MACACA MULATTA; MALE; METABOLIC CLEARANCE RATE; MOLECULAR STRUCTURE; PRODRUGS; PURINE NUCLEOSIDES; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; TISSUE DISTRIBUTION;

EID: 0032808063     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299309667     Document Type: Article

References (23)

1. Kim HO, Schinazi RF, Nampalli S, Shanmuganathan K, Cannon DL, Alves AJ, Jeong LS, Beach JW, and Chu CK: 1,3-Dioxolanylpurine nucleosides (2R, 4R) and (2R, 4S) with selective anti-HIV-1 activity in human lymphocytes. J Med Chem 1993;36: 30-37.
2. Schinazi RF, McClure HM, Boudinot FD, Jxiang Y, and Chu CK: Development of (-)-β-D-2,6-diaminopurine dioxolane as a potential antiviral agent. Antiviral Res 1994;23(Suppl.):81.
3. Institute of Laboratory Animal Resources, National Research Council: Guide for the Care and Use of Laboratory Animals. National Academy Press, Washington, D.C., 1996.
4. Rajagopalan P, Gao Z, Chu CK, Schinazi RF, McClure HM, and Boudinot FD: High-performance liquid chromatographic determination of (-)-β-D-2,6-diaminopurine dioxolane and its metabolite, dioxolane guanosine, using ultraviolet and on-line radiochemical detection. J Chromatogr B 1995;672:119-124.
5. Rocci ML and Jusko WJ: LAGRAN program for area and moments in pharmacokinetic analysis. Comput Prog Biomed 1983;16:203-216.
6. Metzler DM, Elfring GL, and McEwen AJ: NONLIN, a computer program for nonlinear least-squares regression. Biometrics 1974; 30:562-563.
7. Gibaldi M and Perrier D: Pharmacokinetics, 2nd Ed. Marcel Dekker, New York, 1982, pp. 53-60.
8. Gerlowski LE and Jain RK: Physiologically based pharmacokinetic modeling: Principles and applications. J Pharm Sci 1983;72: 1103-1127.
9. Nelson JA, Vidale E, and Enigbokan M: Renal transepithelial transport of nucleosides. Drug Metab Dispos 1988;16:789-792.
10. Patel BA, Chu CK, and Boudinot FD: Pharmacokinetics and saturable renal tubular secretion of zidovudine in rats. J Pharm Sci 1989;78:530-534.
11. Ho DHW, Pincus C, Carter CJ, Benjamin RS, Freirerch EJ, and Bodey GP: Distribution and inhibition of adenosine deaminase in tissues of man, rat, and mouse. Cancer Treatment Rep 1980;64: 629-633.
12. Ceron CR, Caldas RD, Felix CR, Mundim MH, and Roitman I: Purine metabolism in trypanosomatids. J Protozool 1979;26: 479-483.
13. Cretton EM, Zhou Z, Kidd LB, McClure HM, Kaul S, Hitchcock JM, and Sommadossi J-P: In vitro and in vivo disposition and metabolism of 3′-deoxy-2′,3′-didehydrothymidine. Antimicrob Agents Chemother 1993;37:1816-1825.
14. Ho DD, Rota TR, Schooley RT, Kaplain JC, Allan JC, Groopman LE, Resnick L, Felsentein D, Andrew CA, and Hirsch MS: Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med 1985;313:1493-1497.
15. Boudinot FD, Schinazi RF, Gallo JM, McClure HM, Anderson DC, Doshi KJ, Kambhampathi PC, and Chu CK: 3′-Azido-2′, 3′-dideoxyuridine (AzddU): Comparative pharmacokineties with 3′-azido-3′-deoxythymidine (AZT) in monkeys. AIDS Res Hum Retroviruses 1990;6:219-228.
16. Wientjes MG, Mukherji E, and Au JL-S: Nonlinear disposition of intravenous 2′,3′-dideoxyinosine in rats. Pharm Res 1992;9: 1070-1075.
17. Ibrahim SS and Boudinot FD: Pharmacokinetics of 2′,3′-dideoxycytidine in rats: Application to interspecies scale-up. J Pharm Pharmacol 1988;41:829-834.
18. Boudinot FD, Smith SG, Funderburg ED, and Schinazi RF: Pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-deoxy-2′,3′-didehydrothymidine in rats. Antimicrob Agents Chemother 1991; 35:747-749.
19. Kelley JA, Litterst CL, Roth JS, Vistica DT, Poplack DG, Cooney DA, Nadkarni M, Balis FM, Broder S, and Johns DG: The disposition and metabolism of 2′,3′-dideoxycytidine, an in vitro inhibitor of human T-lymphotrophic virus type in infectivity, in mice and monkeys. Drug Metab Dispos 1987;15:595-601.
20. Qian M, Finco TS, Swagler AR, and Gallo JM: Pharmacokinetics of 2′,3′-dideoxyinosine in rhesus monkeys. Antimicrob Agents Chemother 1991;35:1247-1249.
21. Schinazi RF, Boudinot FD, Doshi KJ, and McClure HM: Pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-deoxy-2′, 3′-didehydrothymidine in rhesus monkeys. Antimicrob Agents Chemother 1990;34:1214-1219.
22. Blaney SM, Daniel MJ, Harker AJ, Godwin K, and Balis FM: Pharmacokinetics of lamivudine and BCH-189 in plasma and cerebrospinal fluid of nonhuman primates. Antimicrob Agents Chemother 1995;39:2779-2780.
23. Schinazi RF, Boudinot FD, Manouilov KK, Mellors JW, McMillan A, Schlueter-Wirtz S, Lloyd R Jr, Korba BE, Tennant B, and Chu CK: Anti-HBV and anti-HIV activities of dioxolane-purine nucleosides. In: Program Abstracts: Ninth Int. Conf. Antiviral Res., Urabandai, Fukushima, Japan. 1996, p. 24.